Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
NCT07839871
This study is recruiting at 5 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Respiratory Syncytial Virus (RSV)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- November 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- Duke Vaccine and Trials Unit · Durham, NC
Ohio · 2
- Cincinnati Children's Hospital Medical Center Vaccine Research Center · Cincinnati, OH
- Senders Pediatrics · South Euclid, OH
Washington · 2
- Seattle Children's Hospital · Seattle, WA
- Seattle Childrens Research Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.